Helsinn Therapeutics – Discontinuation of Truseltiq® (infigratinib)
November 17, 2022 - · Helsinn Therapeutics recently announced the discontinuation of Truseltiq (infigratinib) because of difficulties in recruiting and enrolling study participants for the required confirmatory trial. The discontinuation is not due to safety or efficacy reasons.
Top